Overview
UK-US genetic medicines firm's 2025 revenue surged
Company reported a narrower net loss for 2025 compared to prior year
Outlook
MeiraGTx believes it has capital to fund operations into H2 2027, excluding potential milestone payments
Result Drivers
LILLY COLLABORATION - License revenue increased due to a $75 mln upfront payment from Eli Lilly for the AAV-AIPL1 program and related assets
SERVICE REVENUE DECLINE - Service revenue and related costs fell as Johnson & Johnson manufacturing work was substantially completed in H1 2025
R&D SPENDING - Research and development expenses rose due to increased manufacturing costs and higher activity in clinical and preclinical programs, partly offset by lower AAV-hAQP1 costs
Company press release: ID:nGNX312C4s
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY EPS | -$1.42 | ||
FY Net Income | -$114.20 mln | ||
FY Income from Operations | -$105.97 mln | ||
FY Operating Expenses | $187.36 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for MeiraGTx Holdings PLC is $29.00, about 280.6% above its March 25 closing price of $7.62
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments